Faleck, D., Winters, A., Chablaney, S., Shashi, P., Meserve, J., Weiss, A., Aniwan, S., Koliani-Pace, J. L., Kochhar, G., Boland, B., Singh, S., Hirten, R., Shmidt, E., Lasch, K., Luo, M., Bohm, M., Sagi, S. V., Fischer, M., Hudesman, D., Chang, S., Lukin, D., Sultan, K., Swaminath, A., Gupta, N., Siegel, C. A., Shen, B., Sandborn, W. J., Kane, S., Loftus, E. V., Sands, B. E., Colombel, J. -., Dulai, P. S., & Ungaro, R. (n.d.). dOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn's disease but not ulcerative colitis: a multi-centre consortium analysis. Journal of Crohn's and colitis, 12, S066. http://access.bl.uk/ark:/81055/vdc_100095512897.0x000011